ResMed Inc stock (US75102W1036): Strong earnings offset by market underperformance

ResMed delivered solid Q1 2026 results with revenue growth and EPS beating estimates, yet shares continue to lag despite operational strength.

ResMed Inc reported strong quarterly results in early May 2026, with revenue reaching $1.43 billion, up 10.8% year-over-year, and earnings per share of $2.86 topping analyst estimates, according to MarketBeat as of May 14, 2026. Operating income also increased 22% during the period. Despite these operational gains, the stock has underperformed broader market indices, trading at $202.37 on the New York Stock Exchange as of May 14, 2026, down 0.70% on the day, according to ResMed investor relations as of May 14, 2026.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc
• Sector/industry: Healthcare technology, cloud-connected medical devices
• Headquarters/country: United States
• Core markets: Digital health, out-of-home care, hospital software
• Key revenue drivers: Cloud-connected devices, software platforms, care coordination solutions
• Home exchange/listing venue: NYSE (RMD)
• Trading currency: USD

ResMed Inc: core business model

ResMed operates as a global leader in digital health and cloud-connected medical devices, serving patients with chronic respiratory, sleep, and cardiac conditions. The company's business spans three primary segments: out-of-home care, hospital software, and cloud-connected care. ResMed's platform integrates hardware, software, and data analytics to enable remote patient monitoring and care coordination, positioning the company at the intersection of healthcare delivery and digital transformation. This model generates recurring revenue through software subscriptions and device sales to hospitals, home care providers, and individual patients across North America, Europe, and Asia-Pacific markets.

Main revenue and product drivers for ResMed Inc

The company's revenue growth is driven by increasing adoption of cloud-connected devices for sleep apnea, COPD, and cardiac monitoring, combined with expanding software-as-a-service offerings for care coordination. ResMed's digital health platforms enable providers to manage patient populations more efficiently, reducing hospital readmissions and improving outcomes. The out-of-home care segment, which includes ventilators and respiratory devices, remains a significant revenue contributor. Additionally, ResMed's hospital software solutions address workflow optimization and patient data management, creating sticky, recurring revenue streams. Quarterly results demonstrate consistent double-digit revenue growth, with operating leverage improving as the company scales its software and cloud infrastructure.

Why ResMed matters for US investors

ResMed is a major player in the US healthcare technology sector, with substantial exposure to the aging population and rising chronic disease prevalence. The company's NYSE listing and US-based operations make it directly relevant to American equity investors seeking exposure to digital health trends. ResMed's recurring software revenue model and international diversification provide defensive characteristics during economic uncertainty, while its growth trajectory aligns with secular trends in remote patient monitoring and value-based care adoption across US healthcare systems.

Conclusion

ResMed delivered solid operational performance in early 2026, with revenue and earnings growth demonstrating the underlying strength of its digital health platform and recurring software revenue model. However, the stock's recent underperformance relative to market indices suggests investors may be pricing in concerns about valuation, competitive pressures, or broader healthcare sector dynamics. The company's strong fundamentals and exposure to secular healthcare trends remain intact, though near-term market sentiment appears cautious. Investors should monitor upcoming guidance, software adoption rates, and international expansion progress as key indicators of sustained growth momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.